BC006779 Activators
BC006779 activators encompass a diverse range of chemical compounds that affect various cellular processes and signaling pathways, ultimately impacting the function of BC006779. For instance, Nifedipine, an L-type calcium channel blocker, can indirectly increase the activity of BC006779 through intracellular calcium-dependent signaling pathways. Similarly, IBMX, a non-selective inhibitor of cyclic nucleotide phosphodiesterases, leads to the accumulation of cAMP and cGMP in cells that can activate PKA and PKG pathways, respectively, which can then phosphorylate BC006779, enhancing its functional activity.
Among the BC006779 activators, Calyculin A, a potent inhibitor of protein phosphatases PP1 and PP2A, maintains BC006779 in an activated state by inhibiting its dephosphorylation. Similarly, Anisomycin, a JNK activator, leads to the phosphorylation of BC006779, enhancing its functional activity. Epinephrine, an adrenergic receptor agonist, stimulates downstream signaling pathways leading to the phosphorylation and activation of BC006779. Chemicals such as LY294002, U0126, Y-27632, PD98059, KN-93, Akti-1/2, and SB203580 are inhibitors of PI3K, MEK, ROCK, CaMKII, Akt, and p38 MAPK, respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is an L-type calcium channel blocker. By inhibiting calcium influx, it can indirectly increase the activity of BC006779 through intracellular calcium-dependent signaling pathways that BC006779 is involved in. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of cyclic nucleotide phosphodiesterases (PDEs). It leads to the accumulation of cAMP and cGMP in cells. These cyclic nucleotides can activate PKA and PKG pathways, respectively, which can then phosphorylate BC006779, enhancing its functional activity. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is a potent inhibitor of protein phosphatases PP1 and PP2A. By inhibiting the dephosphorylation of BC006779, it maintains BC006779 in an activated state. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator. By activating JNK, it can lead to the phosphorylation of BC006779, enhancing its functional activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine is an adrenergic receptor agonist. By activating adrenergic receptors, it can stimulate downstream signaling pathways that lead to the phosphorylation and activation of BC006779. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor. By inhibiting ROCK, it can stimulate compensatory signaling pathways that lead to the phosphorylation and activation of BC006779. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor. By inhibiting MEK, it can stimulate compensatory signaling pathways that lead to the phosphorylation and activation of BC006779. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a CaMKII inhibitor. By inhibiting CaMKII, it can stimulate compensatory signaling pathways that lead to the phosphorylation and activation of BC006779. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 is a selective Akt inhibitor. The inhibition of Akt can trigger compensatory signaling pathways that phosphorylate and activate BC006779. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it can stimulate compensatory signaling pathways that lead to the phosphorylation and activation of BC006779. | ||||||